A Study of CAR-T Cells Targeting GPRC5D in the Treatment of r/r Multiple Myeloma

Summary

This is a single-arm, open-label, dose-escalation study to evaluate the safety, tolerability, cellular kinetics and initial efficacy of CAR-T cell therapy targeting GPRC5D in multiple myeloma subjects who have failed the standard treatments.

Timeline

Start

2021-06-08

Primary completion

2024-06-30

Completion

2025-06-30

Outcome

Met primary endpoint

release “As of January 16, 2024, all ten patients responded well to OriCAR-017, with the last patient having completed a 24-months follow-up.” oricell.com ↗

release “The overall response rate (ORR) was 100.0%, with a stringent complete response rate (sCR) of 80.0% and a very good partial response rate (VGPR) of 20.0%.” oricell.com ↗

Publications

• Zhang M, Wei G, Zhou L, Zhou J, Chen S, Zhang W, Wang D, Luo X, Cui J, Huang S, Fu S, Zhou X, Tang Y, Ding X, Kuang J, He XP, Hu Y, Huang H. GPRC5D CAR T cells (OriCAR-017) in patients with relapsed or refractory multiple myeloma (POLARIS): a first-in-human, single-centre, single-arm, phase 1 trial. Lancet Haematol. 2023 Feb;10(2):e107-e116. doi: 10.1016/S2352-3026(22)00372-6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	OriCAR-017	Cell therapy	1e+06 cells/kg	Intravenous
Subject	OriCAR-017	Cell therapy	3e+06 cells/kg	Intravenous
Subject	OriCAR-017	Cell therapy	6e+06 cells/kg	Intravenous

Indications